Four independent studies published in the Journal of Thoracic Oncology (JTO) demonstrate that rovalpituzumab tesirine for small-cell lung cancer (SCLC) is not effective against SCLC, casting a pall over the future of the therapy and closing a door that seemed opened four years ago when the first study on the therapy was published. The JTO is the official journal of the International Association for the Study of Lung Cancer.
AbbVie has announced its intention to terminate development of Rova-T (rovalpituzumab tesirine) in the first-line maintenance of advanced small-cell lung cancer (SCLC).
AbbVie is slashing 178 jobs from its Stemcentrx subsidiary in South San Francisco.
Abbvie to record $4 billion impairment charges on Stemcentrx assets
On Friday the company filed a notice with the SEC explaining that AbbVie $ABBV has decided to knock $4 billion off the book value of the drug weeks after researchers were forced to stop recruiting patients in the now infamous TAHOE study.
With the $10 billion Rova-T program seemingly headed toward the cliff, AbbVie is turning to an early-stage collaboration for a longer shot at cancer drug success.
AbbVie $ABBV has managed to convince at least one prominent analyst that Rova-T is absolutely worthless, as the company’s vision of a $5 billion earner gradually dissolves.
AbbVie announced positive topline results from its SELECT-EARLY Phase III clinical trial in rheumatoid arthritis.